Alí Duarte, MD

Advancing the development of criteria for identifying individuals at risk of developing lupus coordinated by Karen Costenbader @MartaMartamosca @AliDuarteMD @MariaTektonidou and cols #ELM2026 @SLEuroSociety #lupus

@wisit661 @ASNKidney No rheumatologist?!

Happy 😊 to see our recent work featured today in ASN In the Loop. @ASNKidney Kidney involvement in primary Sjögren’s syndrome remains underrecognized yet clinically meaningful. In this biopsy-confirmed cohort from Mayo Clinic (2012–2025), we examined clinicopathologic patterns, treatment response, and long-term outcomes in patients with renal involvement. @jingmiao2019 @MayoClinicNeph Several findings stand out: • Tubulointerstitial nephritis was the most common lesion • Baseline CKD was highly prevalent • Immunosuppressive therapy was frequently used, with substantial rates of complete recovery • However, long-term risk remained significant, with nearly half reaching a composite outcome of CKD progression, kidney failure, or death • Higher baseline creatinine, proteinuria, and segmental glomerulosclerosis were associated with poorer recovery and worse prognosis Renal involvement in Sjögren’s syndrome is uncommon, but when present, it carries important prognostic implications. Early recognition, biopsy-guided classification, and risk stratification matter. Grateful to collaborate with an outstanding team on this work. Title: Clinicopathologic Features and Prognostic Factors in Biopsy-Confirmed Renal Involvement in Primary Sjögren’s Syndrome Authors: Charat Thongprayoon; Wisit Cheungpasitporn; Alessia Buglioni; Ladan Zand; Fernando Fervenza; Jing Miao

@BarjonCar @NatureMedicine Felicidades! Increíble portada

Last month, I published part of my PhD thesis in @NatureMedicine : Clinical genetic variation across Hispanic populations in the Mexican Biobank. 🔗 nature.com/articles/s4159… ... and we got the cover of the February issue!

Grateful to the legendary Sanjeev Sethi for partnering with our team.

Bottom line: MCCS and NIH-CI are comparable and add prognostic signal beyond clinical data—with IF/TA doing most of the heavy lifting—and performance was consistent in Class V LN. MCCS may offer a practical edge by aligning chronicity grading across glomerular diseases.

In lupus nephritis (LN), “activity” gets the spotlight—but chronic scarring often decides the long game. So: which chronicity score best predicts outcomes—NIH Chronicity Index (NIH-CI) or the Mayo Clinic Chronicity Score (MCCS)? buff.ly/tvebmPZ